NO953652D0 - Hydroksaminsyrederivater som metalloproteinaseinhibitorer - Google Patents

Hydroksaminsyrederivater som metalloproteinaseinhibitorer

Info

Publication number
NO953652D0
NO953652D0 NO953652A NO953652A NO953652D0 NO 953652 D0 NO953652 D0 NO 953652D0 NO 953652 A NO953652 A NO 953652A NO 953652 A NO953652 A NO 953652A NO 953652 D0 NO953652 D0 NO 953652D0
Authority
NO
Norway
Prior art keywords
alkyl
group
phenyl
pct
hydrogen atom
Prior art date
Application number
NO953652A
Other languages
English (en)
Norwegian (no)
Other versions
NO953652L (no
Inventor
Michael John Crimmin
Raymond Paul Beckett
Mark Hampton Davis
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939305348A external-priority patent/GB9305348D0/en
Priority claimed from GB939320360A external-priority patent/GB9320360D0/en
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of NO953652D0 publication Critical patent/NO953652D0/no
Publication of NO953652L publication Critical patent/NO953652L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO953652A 1993-03-16 1995-09-15 Hydroksaminsyrederivater som metalloproteinaseinhibitorer NO953652L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939305348A GB9305348D0 (en) 1993-03-16 1993-03-16 Hydroxamic acid derivatives as metalloproteinase inhibitors
GB939320360A GB9320360D0 (en) 1993-10-02 1993-10-02 Hydroxamic acid derivatives as metalloproteinase inhibitors
PCT/GB1994/000495 WO1994021625A1 (en) 1993-03-16 1994-03-14 Hydroxamic acid derivatives as metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
NO953652D0 true NO953652D0 (no) 1995-09-15
NO953652L NO953652L (no) 1995-09-15

Family

ID=26302598

Family Applications (1)

Application Number Title Priority Date Filing Date
NO953652A NO953652L (no) 1993-03-16 1995-09-15 Hydroksaminsyrederivater som metalloproteinaseinhibitorer

Country Status (12)

Country Link
US (1) US5652262A (fi)
EP (1) EP0689538B1 (fi)
JP (1) JPH08508027A (fi)
AT (1) ATE169621T1 (fi)
AU (1) AU671724B2 (fi)
CA (1) CA2158352A1 (fi)
DE (1) DE69412469T2 (fi)
FI (1) FI954351A (fi)
GB (1) GB2290543B (fi)
NO (1) NO953652L (fi)
NZ (1) NZ262447A (fi)
WO (1) WO1994021625A1 (fi)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
GB9601042D0 (en) * 1996-01-17 1996-03-20 Smithkline Beecham Plc Medical use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
GB9502858D0 (en) * 1995-02-14 1995-04-05 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
AU5002196A (en) * 1995-03-28 1996-10-16 Novo Nordisk A/S Immunosuppressive agents
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
AU2986295A (en) * 1995-07-19 1997-02-18 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
AU711804B2 (en) 1995-11-23 1999-10-21 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9609702D0 (en) 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
US6169075B1 (en) 1996-09-10 2001-01-02 British Biotech Pharmaceuticals Limited Cytostatic agents
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
JP3973748B2 (ja) * 1998-01-14 2007-09-12 花王株式会社 発毛抑制剤
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
BR0007491A (pt) * 1999-01-13 2001-11-20 Jomaa Pharmaka Gmbh Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
GB9901863D0 (en) * 1999-01-29 1999-03-17 British Biotech Pharm Antibacterial agents
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
CA2415954A1 (en) 2000-07-19 2003-01-17 Kazuhiro Maeda Sulfonic acid derivatives of hydroxamic acids and their use as medicinal products
WO2004073599A2 (en) * 2003-02-18 2004-09-02 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
AU2003227952A1 (en) * 2003-05-17 2004-12-03 British Biotech Pharmaceuticals Ltd Metalloproteinase inhibitors
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
JP2007528409A (ja) 2004-03-09 2007-10-11 アリバ ファーマシューティカルズ, インコーポレイテッド プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
DK0489579T3 (da) * 1990-12-03 1995-06-12 Celltech Therapeutics Ltd Peptidylderivater
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives

Also Published As

Publication number Publication date
GB9517704D0 (en) 1995-11-01
ATE169621T1 (de) 1998-08-15
FI954351A0 (fi) 1995-09-15
DE69412469D1 (de) 1998-09-17
EP0689538B1 (en) 1998-08-12
AU6213194A (en) 1994-10-11
US5652262A (en) 1997-07-29
JPH08508027A (ja) 1996-08-27
AU671724B2 (en) 1996-09-05
WO1994021625A1 (en) 1994-09-29
GB2290543B (en) 1996-05-22
FI954351A (fi) 1995-09-15
NO953652L (no) 1995-09-15
DE69412469T2 (de) 1999-02-04
GB2290543A (en) 1996-01-03
CA2158352A1 (en) 1994-09-29
NZ262447A (en) 1996-07-26
EP0689538A1 (en) 1996-01-03

Similar Documents

Publication Publication Date Title
NO953652D0 (no) Hydroksaminsyrederivater som metalloproteinaseinhibitorer
DK96691A (da) Hydroxamsyrebaserede collagenaseinhibitorer
KR927003624A (ko) 화합물
NZ330922A (en) Hydroxamic acid derivatives substituted by a series of 2-pyrrolidinones, hydantoins, and pyrazolidinones for use with the treatment of diseases related to connective tissue degradation
ATE279391T1 (de) Anti-imflammtorische indolderivate
BR9503582A (pt) Composto composiçao farmaceutica utilizaçao e método de tratamento de um ser humano
ATE192036T1 (de) Vorrichtung für die vaginale verabreichung von tamoxifen und dessen analogen
DK1295871T3 (da) Vitamin D-derivater med et 22-oxa- eller 22-thiaatom, en C17-sidekæde substitueret med en syre-, ester- eller amid-gruppe og en 16(17)-dobbeltbinding
DE69723258T2 (de) Thiadiazolyl(thio)harnstoffe und ihre verwendung als matrix-metallprotease inhibitoren
NO305165B1 (no) 1-Arylcykloalkylsulfider, -sulfoksyder og -sulfoner, farmas°ytiske preparater og anvendelse derav
EP1252890A4 (en) MEDICINAL AND PREVENTIVE AGENTS FOR DIGESTIVE DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE COMPOUNDS
IL122247A0 (en) Use of sulfamic acid derivatives acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
DE69414396T2 (de) Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten
EP1252891A4 (en) MEDICINES FOR THE TREATMENT AND PREVENTION OF HEPATIC CONDITIONS, BASED ON DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES
NZ505994A (en) Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
IT1244696B (it) Derivato chinolonico ad attivita' antibatterica e mucolitica
CO4780024A1 (es) Nuevos derivados del acido hidroxamico utiles para el tratamiento de enfermedades relacionadas con la degradacion del tejido conectivo
MX9709275A (es) Uso de los derivados del acido sulfamico, carbamatos acil sulfonamidas o sulfonil para la manufactura de un medicamento para disminuir los niveles de lipoproteinas.